Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Drop in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 43,200 shares, a drop of 70.6% from the June 30th total of 147,000 shares. Based on an average trading volume of 711,600 shares, the short-interest ratio is currently 0.1 days. Approximately 1.6% of the company’s shares are short sold.

Institutional Investors Weigh In On Senti Biosciences

An institutional investor recently raised its position in Senti Biosciences stock. ARK Investment Management LLC grew its stake in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) by 7.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,969,860 shares of the company’s stock after purchasing an additional 143,785 shares during the period. ARK Investment Management LLC owned approximately 4.42% of Senti Biosciences worth $1,300,000 as of its most recent SEC filing. 25.73% of the stock is currently owned by institutional investors.

Senti Biosciences Trading Up 2.2 %

Shares of SNTI traded up $0.05 during trading hours on Thursday, reaching $2.32. 12,206 shares of the company traded hands, compared to its average volume of 331,671. The company’s fifty day moving average price is $3.03 and its two-hundred day moving average price is $3.67. Senti Biosciences has a 12 month low of $2.11 and a 12 month high of $10.90.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, May 9th. The company reported ($2.60) earnings per share for the quarter. Sell-side analysts anticipate that Senti Biosciences will post -10 EPS for the current year.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.